The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite
Review published in J Cardiothorac Vasc Anesth (2020)
Abstract
Anticoagulation is an essential component for patients undergoing cardiopulmonary bypass or extracorporeal membrane oxygenation and for those with ventricular assist devices. However, thrombosis and bleeding are common complications. Heparin continues to be the agent of choice for most patients, likely owing to practitioners' comfort and experience and the ease with which the drug's effects can be reversed. However, especially in pediatric cardiac surgery, there is increasing interest in using bivalirudin as the primary anticoagulant. This drug circumvents certain problems with heparin administration, such as heparin resistance and heparin-induced thrombocytopenia, but it comes with additional challenges. In this manuscript, the authors review the literature on the emerging role of bivalirudin in pediatric cardiac surgery, including its use with cardiopulmonary bypass surgery, extracorporeal membrane oxygenation, ventricular assist devices, and interventional cardiology. Moreover, they provide an overview of bivalirudin's pharmacodynamics and monitoring methods.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Review of bivalirudin pharmacodynamics and use in pediatric cardiac surgery including CPB, ECMO, VAD and interventional cardiology, particularly for heparin resistance and HIT.
Por qué esto importa para la hirudoterapia
Esta revisión examina el papel emergente de la bivalirudina como anticoagulante alternativo en cirugía cardíaca pediátrica, incluyendo su uso con circulación extracorpórea, oxigenación por membrana extracorpórea, dispositivos de asistencia ventricular y cardiología intervencionista. Los autores examinan la literatura sobre la farmacodinámica de la bivalirudina, los métodos de monitorización y su capacidad para eludir los problemas asociados a la heparina, tales como la resistencia a la heparina y la trombocitopenia inducida por heparina. El resumen no menciona la hirudina, las sanguijuelas ni ninguna conexión con el secretoma de la sanguijuela, por lo que no puede establecerse ningún vínculo defendible con la hirudoterapia a partir de este artículo. Se trata de un artículo de revisión sin datos clínicos originales y no involucra sanguijuelas ni hirudoterapia.
Citación
The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite.
Goswami D et al. · Journal of cardiothoracic and vascular anesthesia, 2020
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026